Dorsey Asset Management LLC Sells 120,122 Shares of Enovis Corporation $ENOV

Dorsey Asset Management LLC reduced its position in shares of Enovis Corporation (NYSE:ENOV) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,279,200 shares of the company’s stock after selling 120,122 shares during the period. Enovis accounts for about 5.3% of Dorsey Asset Management LLC’s investment portfolio, making the stock its 10th largest position. Dorsey Asset Management LLC owned about 3.99% of Enovis worth $60,718,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Arax Advisory Partners acquired a new stake in shares of Enovis during the 4th quarter worth about $29,000. EverSource Wealth Advisors LLC boosted its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Enovis during the 3rd quarter worth about $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Enovis during the 3rd quarter worth about $80,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 4,200 shares of company stock valued at $92,084 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Enovis Trading Up 2.8%

Shares of ENOV stock opened at $21.56 on Wednesday. The firm has a market cap of $1.24 billion, a P/E ratio of -1.08 and a beta of 1.38. Enovis Corporation has a 1-year low of $20.55 and a 1-year high of $36.82. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The firm’s 50-day simple moving average is $23.97 and its 200-day simple moving average is $24.44.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. During the same period in the prior year, the firm posted $0.81 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts forecast that Enovis Corporation will post 3.65 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ENOV. Evercore reiterated an “outperform” rating and set a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Finally, William Blair began coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating on the stock. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.